In mouse models of pancreatic cancer, combining HNVs with α PD-1 therapy effectively suppresses tumor growth, induces innate immune activation, inhibits tumor oxidative phosphorylation, remodels the tumor immune microenvironment, and enhances therapeutic outcomes (110). The gene discussed is PDCD1; the disease is neoplasm.